Corvus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CEORichard A. Miller
CEORichard A. Miller
Employees28
Employees28
HeadquartersBurlingame, California
HeadquartersBurlingame, California
Founded2014
Founded2014
Employees28
Employees28
CRVS Key Statistics
Market cap70.62M
Market cap70.62M
Price-Earnings ratio-2.55
Price-Earnings ratio-2.55
Dividend yield—
Dividend yield—
Average volume130.90K
Average volume130.90K
High today$1.49
High today$1.49
Low today$1.39
Low today$1.39
Open price$1.39
Open price$1.39
Volume130.63K
Volume130.63K
52 Week high$4.19
52 Week high$4.19
52 Week low$0.9777
52 Week low$0.9777
CRVS News
Yahoo Finance 6d
Here's Why Corvus is Poised for a Turnaround After Losing -25% in 4 Weeks - Yahoo FinanceCorvus Pharmaceuticals (CRVS) has been on a downward spiral lately with significant selling pressure. After declining 25% over the past four weeks, the stock lo...
